title: Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
abstract: Atopic dermatitis results when aberrant barrier function and immune activation occur within the skin. Standard therapies for atopic dermatitis have fallen short, prompting efforts to discover novel therapeutics for this disease. Of these, dupilumab, a fully human monoclonal antibody that inhibits the actions of both IL-4 and IL-13, has shown the greatest promise. Clinical trials of systemic dupilumab in moderate-to-severe atopic dermatitis have demonstrated marked improvement in patient symptoms, including pruritus and clinically visible disease. Importantly, dupilumab treatment has been correlated with changes in the molecular signature of diseased skin, with reduction of both inflammatory and proliferative markers. Dupilumab recently received US FDA breakthrough therapy designation for atopic dermatitis, with ongoing trials in both adult and pediatric populations. Altogether, dupilumab has shed new light on the pathomechanisms driving atopic dermatitis and is making unprecedented advances towards highly effective control of this debilitating disease.
authors.affiliation: University of Toronto, Faculty of Medicine, Toronto, ON, Canada.
authors.forename: K
authors.initials: K
authors.lastname: Blakely
authors.affiliation: Skin Centre for Dermatology, Peterborough, ON, Canada; Probity Medical Research, Waterloo, ON Canada.
authors.forename: M
authors.initials: M
authors.lastname: Gooderham
authors.affiliation: K. Papp Clinical Research, Waterloo, ON, Canada; Probity Medical Research, Waterloo, ON Canada.
authors.forename: K
authors.initials: K
authors.lastname: Papp
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D018793:Interleukin-13 / Q000037:antagonists & inhibitors*; D015847:Interleukin-4 / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018793:Interleukin-13; D015847:Interleukin-4; C582203:dupilumab